For the year ending 2025-12-31.
| Income Statement | 2025-12-31 | |||
|---|---|---|---|---|
| General & administrative | 1,253,203 | |||
| Research & development | 2,985,873 | |||
| Total operating expenses | 4,239,076 | |||
| Loss from operations | -4,239,076 | |||
| Interest expense | 8,537 | |||
| Other income | 22,507 | |||
| Net loss | -4,225,106 | |||
| Basic EPS | -0.17 | |||
| Diluted EPS | -0.17 | |||
| Basic Average Shares | 25,497,328 | |||
| Diluted Average Shares | 25,497,328 | |||
Curanex Pharmaceuticals Inc (CURX)
Curanex Pharmaceuticals Inc (CURX)